Login to Your Account



Sanofi pads MS pipeline with Principia's BTK inhibitor in potential $805M pact

By Marie Powers
News Editor

Thursday, November 9, 2017

With an eye to sustaining its multiple sclerosis (MS) franchise, Sanofi SA plucked a BTK inhibitor from Principia Biopharma Inc. The Paris-based pharma agreed to pay $40 million up front, with milestone payments that could reach $765 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription